ガイドライン

(旧版)EBMに基づく 胃潰瘍診療ガイドライン 第2版 −H. pylori二次除菌保険適用対応−

書誌情報
第1部 胃潰瘍の基礎知識

 
参考文献

1) 厚生労働省大臣官房統計情報部:厚生労働省統計調査結果.http://www.mhlw.go.jp/toukei/index.html
2) 日本消化器集団検診学会全国集計委員会:平成7〜15年度消化器集団検診学会全国集計 I.胃集検全国集計.日消集検誌,36-44(1998-2006)
3) 塩川優一,延永正,斉藤輝信,他:非ステロイド性抗炎症剤による上部消化管障害に関する疫学調査.リウマチ,31:96-111,1991
4) 羽生泰樹,渡辺能行,川井啓市:どのように消化性潰瘍は変貌しているか.消化器外科,16:1121-6,1993
5) Guha S, Kaunitz JD: Gastroduodenal mucosal defense; an integrated protective response. Curr Opin Gastroenterol, 18:650-7,2002
6) 平石秀幸,島田忠人,寺野彰,(戸田剛太郎・税所宏光・寺野彰・幕内雅敏 編):胃粘膜防御機構.Annual Review 消化器 2001:中外医学社,pp.74-9,2001
7) Jones MK, Tomikawa M, Mohajer B, et al: Gastrointestinal mucosal regeneration: role of growth factors. Front Biosci, 4:D303-9,1999
8) Azuma T, Yamazaki S, Yamakawa A, Ohtani M, Muramatsu A, Suto H, Ito Y, Dojo M, Yamazaki Y, Kuriyama M, Keida Y, Higashi H, Hatakeyama M: Association between diversity in the Src homology 2 domain--containing tyrosine phosphatase binding site of Helicobacter pylori CagA protein and gastric atrophy and cancer. J Infect Dis, 189(5):820-7,2004
9) Yamaoka Y, Kudo T, Lu H, Casola A, Brasier AR, Graham DY: Role of interferon-stimulated responsive element-like element in interleukin-8 promoter in Helicobacter pylori infection. Gastroenterology, 126(4):1030-43,2004
10) Van der Hulst RW, Rauws EA, Köycü B, Keller JJ, Bruno MJ, Tijssen JG, Tytgat GN: Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology, 113(4):1082-6,1997
11) Huang JQ, Sridhar S, Hunt RH: Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet, 359:14-22,2002
12) Sakamoto C, Sugano K, Ota S, et al: Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol, 62:765-72,2006
13) Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med, 340:1888-99,1999
14) Chan FK, Leung WK: Peptic-ulcer disease. Lancet, 360:933-41,2002
15) Borody TJ, Brandl S, Andrews P, Jankiewicz E, Ostapowicz N: Helicobacter pylori-negative gastric ulcer. Am J Gastroenterol, 87:1403-6,1992
16) Jyotheeswaran S, Shah AN, Jin HO, Potter GD, Ona FV, Chey WY: Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol, 93:574-8,1998
17) Nishikawa K, Sugiyama T, Kato M, et al. Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Eur J Gastroenterol Hepatol, 12:635-40,2000
18) Chan HL, Wu JC, Chan FK, et al: Is non-Helicobacter pylori, non-NSAID peptic ulcer a common cause of upper GI bleeding? A prospective study of 977 patients. Gastrointest Endosc, 53:438-42,2001
19) Quan C, Talley NJ: Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs. Am J Gastroenterol, 97:2950-61,2002
20) Nagahara Y, Mizuno M, Maga T, et al: Outcome of patients with inconsistent results from 13C-urea breath test and bacterial culture at the time of assessment of Helicobacter pylori eradication therapy in Japan. Hepatogastroenterology, 50:1700-3,2003
21) 辻晋吾,谷村博久,川野淳:H. pylori(-)消化性潰瘍の実体.消化器内視鏡,9:1021-5,1997
22) Chen JJ, Changchien CS, Tai DI, Chiou SS, Lee CM, Kuo CH: Role of Helicobacter pylori in cirrhotic patients with peptic ulcer. A serological study. Dig Dis Sci, 39:1565-8,1994
23) Graham DY, Malaty HM: Alendronate gastric ulcers. Aliment Pharmacol Ther, 13:515-9,1999
24) Doria MI Jr, Doria LK, Faintuch J, Levin B: Gastric mucosal injury after hepatic arterial infusion chemotherapy with floxuridine. A clinical and pathologic study. Cancer, 73:2042-7,1994
25) 清水京子,白鳥敬子:Zollinger-Ellison症候群―最近の動向.医学のあゆみ,210:490-4,2004
26) 志村貴也,犬飼政美,吉岡宣夫,他:びまん性胃・十二指腸炎を合併した潰瘍性大腸炎の1例.日消誌,103:30-6,2006
27) 原田直彦,千ヶ岩芳春,(竹本忠良 監,中沢三郎・森賀本幸・岡崎幸紀 編):初発時症状.日本消化性潰瘍学:医科学出版社,pp.578-82,1995
28) 永原章仁,宮崎招久,三輪洋人,佐藤信紘:症候論.日本臨牀 H. pylori 時代の消化性潰瘍学,60(増刊号):279-84,2002
29) Silen W, (Silen W ed.) : Perforation of a gastric or duodenal ulcer: Cope's early diagnosis of the acute abdomen, pp.104-18, 2000
30) Rockall TA, Logan RF, Devlin HB, Northfield TC: Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ, 311:222-6,1995
31) 酒井義浩:上部消化管出血.内科,89:1127-31,2002
32) 田辺聡,田尻久雄,赤星和也,(日本消化器内視鏡学会卒後教育委員会 編):18.内視鏡的止血法ガイドライン.消化器内視鏡ガイドライン:医学書院,pp.188-205,2006
33) 日本消化器病学会 Helicobacter pylori 治験検討委員会:Helicobacter pylori 治験ガイドライン.日消誌,96:199-207,1999
34) 日本ヘリコバクター学会ガイドライン作成委員会:Helicobacter pylori 感染の診断と治療のガイドライン.日本ヘリコバクター学会誌,2(suppl):2-12,2000
35) 日本ヘリコバクター学会ガイドライン作成委員会:Helicobacter pylori 感染の診断と治療のガイドライン 2003年改訂版.日本ヘリコバクター学会誌,4(suppl):1-16,2003
36) 山本一成,福田能啓,下山孝,(寺野彰・高橋信一 編):診断時期.ヘリコバクター・ピロリとその除菌法:南江堂(東京),pp79,1999
37) 伊藤俊之,千葉勉:消化性潰瘍.薬局,53(増刊号):658-66,2002
38) 中村孝司:消化性潰瘍薬物療法概論.日本臨牀,60(増刊2号):365-70,2002
39) 原義雄,(吉利和 編):VIII.経過と予後 胃潰瘍の長期経過―再発,再燃,癌化,悪性サイクルなど―.胃・十二指腸潰瘍のすべて 第2版:南江堂,pp.333-45,1979
40) 中村孝司:消化性潰瘍の薬物療法 治療促進と再発の問題について.Prog in Med, 2:873-80,1982
41) Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P: A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther, 15:1949-58,2001
42) 中村孝司:維持療法はどうあるべきか.日内会誌,84:916-21,1995
43) Malfertheiner P, Leodolter A, Peitz U: Cure of Helicobacter pylori-associated ulcer disease through eradication. Baillieres Best Pract Res Clin Gastroenterol, 14:119-32,2000
44) Asaka M, Kato M, Sugiyama T, et al: Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J Gastroenterol, 38:339-47,2003
45) Ford A, Delaney B, Forman D, et al: Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev, (4):CD003840,2004
46) Van der Hulst RW, Rauws EA, Köycü B, et al: Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology, 113:1082-6,1997
47) Miwa H, Sakaki N, Sugano K, et al: Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients. Helicobacter, 9:9-16,2004
48) Asaka M, Satoh K, Sugano K, et al: Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter, 6:177-86,2001
49) Asaka M, Sugiyama T, Kato M, et al: A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter, 6:254-61,2001
50) Malfertheiner P, Megraud F, O'Morain C, et al: Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut, 56:772-81,2007 Jun 17 [Epub 2006 Dec 14]
51) Nagahara A, Miwa H, Ohkura R, et al: Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection. J Gastroenterol Hepatol, 16:613-8,2001
52) Isomoto H, Inoue K, Furusu H, et al: High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Aliment Pharmacol Ther, 18:101-7,2003
53) Murakami K, Sato R, Okimoto T, et al: Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther, 17:119-23,2003
54) Miwa H, Nagahara A, Kurosawa A, et al: Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment Pharmacol Ther, 17:1545-51,2003
55) Shimoyama T, Fukuda S, Mikami T, Fukushi M, Munakata A: Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. J Gastroenterol, 39:927-30,2004
56) 塩川優一,延永正,斉藤輝信,他:非ステロイド性抗炎症剤による上部消化管障害に関する疫学調査.リウマチ,31:96-111,1991
57) Rosenstock S, Jørgensen T, Bonnevie O, Andersen L: Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults. Gut, 52:186-93,2003
58) Piper DW, Hunt J, Heap TR: The healing rate of chronic gastric ulcer in patients admitted to hospital. Scand J Gastroenterol, 15:113-7,1980
59) Miyoshi M, Mizuno M, Ishiki K, et al: A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J Gastroenterol Hepatol, 16:723-8,2001
60) Kamada T, Haruma K, Komoto K, et al: Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. Helicobacter, 4:204-10,1999
61) Ozawa T, Yoshikawa N, Tomita T, Akita Y, Mitamura K: The influence of feeding on gastric acid suppression in Helicobacter pylori-positive patients treated with a proton pump inhibitor or an H2-receptor antagonist after bleeding from a gastric ulcer. J Gastroenterol. 38:844-8,2003
62) Rydning A, Weberg R, Lange O, Berstad A: Healing of benign gastric ulcer with low-dose antacids and fiber diet. Gastroenterology, 91:56-61,1986
63) Joish VN, Donaldson G, Stockdale W, et al: The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database. Curr Med Res Opin, 21:535-44,2005
64) Habu Y, Inokuchi H, Kiyota K, et al: Economic evaluation of Helicobacter pylori eradication for the treatment of duodenal ulcer disease in Japan: a decision analysis to assess eradication strategy in comparison with a conventional strategy. J Gastroenterol Hepatol, 13:280-7,1998
65) 羽生泰樹,清田啓介,井口秀人,他:消化性潰瘍治療におけるnew triple therapyとdual therapy―除菌率と費用効果の観点から―.日本臨牀,57:135-9,1999
66) 羽生泰樹,大安一也,若松隆宏,他:消化性潰瘍におけるHelicobacter pylori 感染診断法の選択:費用効果の観点から.Helicobacter Research, 5:301-11,2001

 

書誌情報